The Total Economic Impact of Anti-Aquaporin-4 Antibody-Positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD) on Patients and Caregivers in the United States (P7-8.008)
To quantify the total economic impact, including direct, indirect, and nonmedical costs, of AQP4-Ab+ NMOSD on US patients and caregivers.
Authors
- Caitlin Dodd (ORCID: https://orcid.org/0000-0002-8784-696X)
- Asger Hegelund Olsen (ORCID: https://orcid.org/0000-0002-0826-8971)
- Mayvis Rebeira (ORCID: https://orcid.org/0000-0003-0915-3671)
- Jeffrey Yu (ORCID: https://orcid.org/0000-0003-3067-6813)
- Benjamin Osborne
- Evanthia Bernitsas (ORCID: https://orcid.org/0000-0001-9382-1008)
- Justin Lee (ORCID: https://orcid.org/0000-0003-4832-9852)
- Nicole Betor
- Jamie Sullivan
- Lindsey Przybyl
- Jesus Loreto
- Alexis Garduno
Institutions
- Creighton University (US)
- Georgetown University (US)
- Georgetown University Medical Center (US)
- AstraZeneca (Brazil) (BR)
- Alexion Pharma (Switzerland) (CH)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000208721
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00